Literature DB >> 8578850

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.

N Boulianne1, G De Serres, S Ratnam, B J Ward, J R Joly, B Duval.   

Abstract

The levels of antibody against measles, mumps, and rubella were determined at 5-6 years postimmunization in 468 children vaccinated with two different trivalent vaccines. The proportions of children without detectable antibody levels were 12 and 3.6% for measles (p < 0.001), 14.9 and 7% for mumps (p = 0.006), and 3.3 and 3.1% for rubella (p = 0.88), respectively, in MMR II and Trivirix recipients. A higher proportion of those vaccinated at younger ages had undetectable or low levels of measles antibody. These data indicate that a large proportion of children vaccinated under routine conditions do not have detectable measles and mumps antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578850     DOI: 10.1016/0264-410x(95)00098-l

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Neelam Dhiman; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

Review 3.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

4.  Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma.

Authors:  Kwang Ha Yoo; Kanishtha Agarwal; Michael Butterfield; Robert M Jacobson; Gregory A Poland; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2010 Nov-Dec       Impact factor: 2.587

5.  SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine.

Authors:  Neelam Dhiman; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; Megan M O'Byrne; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2010-03-10       Impact factor: 2.846

6.  Vaccination titres pre- and post-transplant in paediatric renal transplant recipients and the impact of immunosuppressive therapy.

Authors:  Britta Höcker; Martin Aguilar; Paul Schnitzler; Lars Pape; Martin Bald; Jens König; Stephen D Marks; Gurkan Genc; Anja Büscher; Markus J Kemper; Heiko Billing; Martin Pohl; Luca Dello Strologo; Nicholas J A Webb; Susanne Rieger; Annette Mankertz; Kai Krupka; Thomas Bruckner; Alexander Fichtner; Burkhard Tönshoff
Journal:  Pediatr Nephrol       Date:  2018-01-10       Impact factor: 3.714

7.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

8.  The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence.

Authors:  Ken Lemon; Bertus K Rima; Stephen McQuaid; Ingrid V Allen; W Paul Duprex
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

10.  Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responses.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2009-11-05       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.